top of page

Sernova Announces Presentation of HemAcure Hemophilia Program Results at 23rd Annual Meeting of...

Sernova Announces Presentation of HemAcure Hemophilia Program Results at 23rd Annual Meeting of the American Society of Gene and Cell Therapy

May 12, 2020 9:00 a.m. EDT

LONDON, ONTARIO – May 12, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage regenerative medicine therapeutics company, is pleased to announce that the Horizon 2020 HemAcure Consortium will present scientific results of the consortium’s research in an abstract entitledCombined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device in an oral presentation during the ASGCT 23rd Annual Meeting, which is being held in virtual format May 12-15, 2020. The abstract will be presented on May 15 at 11:30 am EDT.

The abstract being presented describes scientific results of the HemAcure Consortium’s research to develop a novel ex vivo cell-based therapy for the treatment of Hemophilia A using Sernova’s Cell PouchTM and paves the way for future clinical testing.

Abstract 1359 can be viewed at:

“The Horizon 2020 grant program enabled international experts and innovators in their field, including the Sernova team, to form the HemAcure Consortium to advance the next-generation cell-based regenerative medicine therapy aimed to improve the quality of life for people with hemophilia A. We are excited for members of the HemAcure team to present additional scientific updates at the ASGCT Annual Meeting that further supports Sernova’s technologies and their potential in a novel future therapeutic treatment for hemophilia A,” said Dr. Philip Toleikis, President and CEO of Sernova Corp.

ABOUT HEMACURE The overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, hemophilia A (caused by a genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European Union’s Horizon 2020 research and innovation program has awarded approximately €5.5 million (CDN$8.5) to support the project. International consortium members include the University Hospital Würzburg (Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany, Università del Piemonte Orientale “Amedeo Avogadro,” Novara, Italy, Loughborough University, Loughborough, United Kingdom, ARTTIC International Management Services, Munich, Germany and Sernova Corp., London, Ontario, Canada. For more information, visit

ABOUT SERNOVA’S CELL POUCH SYSTEM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP. Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells ( i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit

FOR FURTHER INFORMATION, PLEASE CONTACT: Dominic Gray Sernova Corp. Tel: (519) 858-5126

FORWARD-LOOKING INFORMATION This release contains statements that to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development

of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic.

Investors should consult the company’s quarterly and annual filings available on for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

#Diabetes #DiabetesResearch #Hemophilia #RegenerativeMedicine #ClinicalTrials #StemCells #Cells #CellBasedTherapy #TherapeuticCells #ChronicMetabolicDiseases #BloodDisorders #TherapeuticCells #Insulin #MedicalResearch #Research #MedicalAdvancements #BiotechStocks #SmallCapStocks #FrontierMCG

Recent Posts

See All
bottom of page